Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05995262 · ClinicalTrials.gov registry record

Effect of a Pharmacist-led, Collaborative Practice on Clinical Outcomes in Persons with Diabetes

A clinical trial of Diabetes and Type 2 Diabetes, sponsored by Methodist Health System.

Active
Registry status
100
Enrollment target
1
Study location

NCT05995262: Active study of Diabetes and Type 2 Diabetes, sponsored by Methodist Health System.

NCT05995262 is a study of Diabetes and Type 2 Diabetes that is active but no longer recruiting, run by Methodist Health System. The registered enrollment target is 100 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05995262, a study of Diabetes and Type 2 Diabetes, is active but no longer recruiting, sponsored by Methodist Health System.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

Diabetes is a complex chronic illness known for its high prevalence (11.3% in the United States), significant healthcare burdens in terms of cost and management, and high mortality rate (seventh leading cause of death in the United States in 2019). Diabetes-related complications including ischemic heart disease, stroke, hyperglycemic crises, amputations, and hypoglycemia accounted for 8.25 million hospital discharges and 25.9% of emergency department visits, contributing towards the $327 billion total cost of diabetes in 2017. Proper treatment of diabetes is integral to reduce a patient's risk of developing complications; however, a number of barriers can create additional burdens for persons with diabetes. Several studies have also demonstrated reductions in hospitalizations and/or ED visits for patients enrolled in pharmacist-led collaborative practice models. While the literature as a whole clearly describes the impact of ambulatory pharmacist intervention in achieving guideline-based clinical goals (i.e., HbA1c, blood pressure), few studies have reported on adherence with guideline-driven pharmacotherapy pre- and post-pharmacist intervention, or on pharmacist impact in reducing medication burden.

Primary Outcome

HbA1c will be evaluated within 90 days prior to the first visit and within 90 days after the last clinic encounter.

Conditions Studied

Interventions

  • OTHER Chart Review

Study Locations (1)

Texas

  • Methodist Dallas Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-04-06
Est. Completion 2025-04-03
Methodist Health System

125 total trials

What the registry record for NCT05995262 still lists

NCT05995262 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Chart Review is the first listed.

NCT05995262 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05995262 about?

NCT05995262 is a clinical study titled "Effect of a Pharmacist-led, Collaborative Practice on Clinical Outcomes in Persons with Diabetes". Diabetes is a complex chronic illness known for its high prevalence (11.3% in the United States), significant healthcare burdens in terms of cost and management, and high mortality rate (seventh leading cause of death in the United States in 2019). Diabetes-related complications including ischemic h...

What is the current status of trial NCT05995262?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-04-06. Estimated completion is 2025-04-03.

What conditions does trial NCT05995262 study?

This clinical trial studies the following conditions: Diabetes, Type 2 Diabetes.

What interventions are being tested in trial NCT05995262?

The interventions under investigation include: Chart Review (OTHER).

Who is sponsoring clinical trial NCT05995262?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05995262 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05995262's enrollment target sits among peer trials

100 191st of 338 higher than 144 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05995262, the US trial registry maintained by the National Library of Medicine. NCT05995262 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.